ライフサイエンスコーパス: meningitis

1 ulous meningitis, and two as not tuberculous meningitis.

2 s on healthcare-associated ventriculitis and meningitis.

3 MTB/RIF Ultra (Xpert Ultra) for tuberculous meningitis.

4 se is untested in patients with cryptococcal meningitis.

5 ed to establish nonhematogenous pneumococcal meningitis.

6 al invasive infections, including sepsis and meningitis.

7 re aggressive treatment than anthrax without meningitis.

8 iagnostic and prognostic factors for anthrax meningitis.

9 umococcus) is the primary cause of bacterial meningitis.

10 T) status for people with a first episode of meningitis.

11 rough the BBB into the brain to cause lethal meningitis.

12 isease severity and outcome in patients with meningitis.

13 tocida is a rare cause of neonatal bacterial meningitis.

14 the blood brain barrier, causing cause fatal meningitis.

15 gens responsible for most cases of bacterial meningitis.

16 s comprising 373 patients with meningococcal meningitis.

17 most frequent and critical type of bacterial meningitis.

18 re more frequently associated with sepsis or meningitis.

19 nfluence the pathophysiology of pneumococcal meningitis.

20 is the second most common cause of neonatal meningitis.

21 with morbidity and mortality of pneumococcal meningitis.

22 GBS) is a major cause of neonatal sepsis and meningitis.

23 ring function in a rat model of pneumococcal meningitis.

24 -1 has the potential to prevent pneumococcal meningitis.

25 GBS infection include sepsis, pneumonia, and meningitis.

26 ents (5.5%) had a suspected ventriculitis or meningitis.

27 o apply to meningococcal meningitis or viral meningitis.

28 ile sites to cause bloodstream infection and meningitis.

29 years with symptoms and signs suggestive of meningitis.

30 confer protection against cardiac damage and meningitis.

31 a for 325 children hospitalized with E. coli meningitis.

32 ens from patients and mice with pneumococcal meningitis.

33 lood-brain barrier during the development of meningitis.

34 al effect on confirmed group A meningococcal meningitis.

35 o are developing and dying from cryptococcal meningitis.

36 isms of CNS entry as well as the severity of meningitis.

37 in the early host response during bacterial meningitis.

38 as 50% (7 of 14) with 1:160-1:320 titers had meningitis.

39 ological diseases including encephalitis and meningitis.

40 al diagnostic test for suspected tuberculous meningitis.

41 ed as significant risk factors for bacterial meningitis.

42 percentage of infants with NDI following GBS meningitis.

43 s initial diagnostic testing for tuberculous meningitis.

44 cipients), one case of Haemophilus influenza meningitis (1% rabies-vaccine recipients), and one case

45 h fungal (13), arboviral (10), and bacterial meningitis (7).

46 nisters of health declared the prevention of meningitis a high priority and asked the World Health Or

47 us pneumoniae is the main cause of bacterial meningitis, a life-threating disease with a high case fa

48 mmon pathogens accounting for most bacterial meningitis, a serious global infectious disease with hig

49 rubii is the causative agent of cryptococcal meningitis, a significant source of mortality in immunoc

50 Acute bacterial meningitis (ABM) in adults residing in resource-poor cou

51 In suspected acute bacterial meningitis (ABM), cerebral computerized tomography (CT)

52 eudosyrinx, without inflammatory evidence of meningitis activity.

53 Trends in viral meningitis admissions have changed substantially over th

54 elop healthcare-associated ventriculitis and meningitis after the following procedures or situations:

55 Admissions for mumps-related meningitis almost disappeared following introduction of

56 with healthcare-associated ventriculitis and meningitis (American Academy of Neurology, American Asso

57 ight into the seasonal dynamics of bacterial meningitis and add to knowledge about the global epidemi

58 Six patients had recurrent episodes of meningitis and all recovered without any neurologic sequ

59 r of morbidity and mortality of pneumococcal meningitis and also suggests a potential role for MIF as

60 a foodborne pathogen that causes septicemia, meningitis and chorioamnionitis and is associated with h

61 Rapid diagnosis and treatment of infectious meningitis and encephalitis are critical to minimize mor

62 Meningitis and encephalitis are potentially life-threate

63 sts for the most common causes of infectious meningitis and encephalitis have the potential for high

64 ers to diagnosis, and current best tests for meningitis and encephalitis in developed countries.

65 es that are transmitted by insects and cause meningitis and encephalitis in subsets of individuals in

66 Viruses are the most common cause of meningitis and encephalitis in the United States and are

67 est Nile virus (WNV) is an emerging cause of meningitis and encephalitis in the United States.

68 Histological analysis revealed signs of meningitis and encephalitis, characteristic of severe hu

69 rapy for children with signs and symptoms of meningitis and encephalitis.

70 sease and severe clinical syndromes, such as meningitis and endocarditis.

71 ial reductions in the incidence of suspected meningitis and epidemic risk, and a substantial effect o

72 ide cohort of 405 patients with pneumococcal meningitis and in 329 controls matched for age, gender,

73 ger, to determine risk factors for bacterial meningitis and invasive bacterial disease.

74 ynx and the causative agent of meningococcal meningitis and meningococcemia, is capable of invading a

75 neumococcus) is a leading cause of bacterial meningitis and neurological sequelae in children worldwi

76 a meningitidis is a major cause of bacterial meningitis and sepsis worldwide.

77 r example, tuberculosis, syphilis, bacterial meningitis and sepsis), fungal (for example, cryptococca

78 ontal genetic exchange, are a major cause of meningitis and septicaemia worldwide.

79 Neisseria meningitidis causes bacterial meningitis and septicemia.

80 mmensal that can also cause life-threatening meningitis and septicemia.

81 o knowledge about the global epidemiology of meningitis and the host, environment, and pathogen chara

82 nts with a first episode of culture-positive meningitis and two or more CSF cultures.

83 osuppression who developed recurrent aseptic meningitis and underwent brain biopsy revealing a diagno

84 th strains, oral infection resulted in focal meningitis and ventriculitis with recruitment of inflamm

85 ng patients with HIV-associated cryptococcal meningitis and was associated with more adverse events a

86 d sepsis), fungal (for example, cryptococcal meningitis) and parasitic (for example, malaria, neurocy

87 ents (5.5%) had a confirmed ventriculitis or meningitis, and 15 patients (5.5%) had a suspected ventr

88 nted with pneumonia, 78 (35%) presented with meningitis, and 16 (7%) had other clinical conditions.

89 sser's disease in swine, with polyserositis, meningitis, and arthritis.

90 sease (IPD) is a leading cause of pneumonia, meningitis, and bacteremia in children.

91 sRNA flavivirus that can cause encephalitis, meningitis, and death in humans and mice.

92 need for inotropes, mechanical ventilation, meningitis, and death, was unchanged after introduction

93 on in pregnant women, as well as septicemia, meningitis, and gastroenteritis, primarily in immunocomp

94 humanized mice was characterized by gliosis, meningitis, and meningoencephalitis, and glial cells wer

95 . coli K1 is a novel pathogenic mechanism in meningitis, and pharmacological upregulation of PPAR-gam

96 3 that caused meningitis, septicemia without meningitis, and septicemia with meningitis, respectively

97 us meningitis, three as possible tuberculous meningitis, and two as not tuberculous meningitis.

98 onths after discharge with symptoms of acute meningitis, and was found to have Ebola virus in cerebro

99 ines for epidemic diseases, such as cholera, meningitis, and yellow fever, have become common over th

100 sis a major endemic pathogen of pigs causing meningitis, arthritis, and other diseases.

101 Cryptococcal meningitis associated with human immunodeficiency virus

102 viding new insights into the pathogenesis of meningitis-associated hearing loss that reveal new start

103 ion of West Africa has the highest bacterial meningitis attack and case fatality rate in the world.

104 surveillance data for nine countries in the meningitis belt (Benin, Burkina Faso, Chad, Cote d'Ivoir

105 A meningococcal vaccine, PsA-TT, in Africa's meningitis belt countries represented the first introduc

106 ies, including from 47 countries outside the meningitis belt in sub-Saharan Africa.

107 ia meningitidis serogroup A epidemics in the meningitis belt of sub-Saharan Africa, a meningococcal s

108 ng mass vaccination campaigns in the African meningitis belt with group A meningococcal conjugate vac

109 conjugate vaccine developed for the African meningitis belt, an enhanced meningitis surveillance net

110 rm control of MenA meningitis in the African meningitis belt.

111 s in the sub-Saharan region of Africa in the meningitis belt.

112 be developed and introduced into the African meningitis belt.

113 auses of bacterial meningitis in the African meningitis belt.

114 ant determinant of mortality in cryptococcal meningitis, but its use in aiding clinical decision maki

115 ons were consistent with chronic lymphocytic meningitis, but no definitive cause was identified.

116 ay contribute to susceptibility of bacterial meningitis, but which genes contribute to the susceptibi

117 Pneumococci cause meningitis by invading the blood and penetrating the blo

118 assified as probable or definite tuberculous meningitis by uniform case definition, excluding Xpert U

119 cture (LP) in adults with community-acquired meningitis (CAM).

120 study in 469 community-acquired pneumococcal meningitis cases and 2072 population-based controls from

121 From Jan 1 to June 30, 2015, 9367 suspected meningitis cases and 549 deaths were reported in Niger.

122 The incidence of suspected meningitis cases declined by 57% (95% CI 55-59) in vacci

123 ounted for 73% of the estimated cryptococcal meningitis cases in 2014 (162 500 cases [95% CI 113 600-

124 In the United States, cryptococcal meningitis causes approximately 3400 hospitalizations an

125 ters >1:640, 96% (27 of 28) had cryptococcal meningitis (cerebrospinal fluid CRAG-positive) whereas 5

126 samples, including bacteremia and bacterial meningitis classified as IBIs.

127 Diagnosing coccidioidal meningitis (CM) can be problematic owing to its infreque

128 eficiency virus/AIDS-associated cryptococcal meningitis (CM) frequently experience clinical deteriora

129 Coccidioidal meningitis (CM) has high morbidity, and adjunctive measu

130 Coccidioidal meningitis (CM) is a devastating complication of coccidi

131 Cryptococcal meningitis (CM) is one of the most common causes of AIDS

132 rmine the national incidence of cryptococcal meningitis (CM), and describe characteristics of cases d

133 defaulted from care, died from cryptococcal meningitis (CM).

134 cases) for probable or definite tuberculous meningitis compared with 43% (23-66; 10/23) for Xpert an

135 Escherichia coli K1 meningitis continues to be a major threat to neonatal he

136 e understanding of global seasonal trends in meningitis could be used to design more effective preven

137 36%) cases with systemic anthrax met anthrax meningitis criteria.

138 temporal manner may indicate early bacterial meningitis development in neurosurgical patients, enabli

139 revent pneumococcal entry into the brain and meningitis development.

140 ioidal, so CSF BG screening can be useful in meningitis diagnosis.

141 en by participants with CSF WCC <5/microL at meningitis diagnosis: 28% (10/36) of such persons in the

142 uid data from all 37 laboratories performing meningitis diagnostics in Botswana were collected from t

143 umber of severe pathologies, such as aseptic meningitis, dilated cardiomyopathy, type I diabetes, par

144 e describe the first 2 cases of eosinophilic meningitis due to Paragonimus kellicotti.

145 Meningitis due to vaccine serotypes nearly disappeared i

146 d assessment tool for screening patients for meningitis during an anthrax mass casualty incident.

147 HIV-infected adults with suspected meningitis (eg, headache, nuchal rigidity, altered menta

148 The FilmArray Meningitis/Encephalitis (ME) Panel is a multiplexed in v

149 vely assess the performance of the FilmArray meningitis/encephalitis panel compared to conventional m

150 We report the first meningitis epidemic in Niger since the nationwide introd

151 de vaccines had been used to control African meningitis epidemics for >30 years but with little or mo

152 After the major group A meningococcal meningitis epidemics in 1996-1997 (250,000 cases and 25,

153 better immunization strategies to eliminate meningitis epidemics in Africa.

154 te vaccine was developed to eliminate deadly meningitis epidemics in sub-Saharan Africa.

155 infect the central nervous system and cause meningitis following the natural route of infection in m

156 uated 129 HIV-infected adults with suspected meningitis for tuberculosis.

157 nsible for 67.3% of 55 cases of eosinophilic meningitis from a cohort of 1,690 adult patients with CN

158 Hospital admission rates for viral meningitis from Jan 1, 1968, to Dec 31, 1985, varied ann

159 y, Toscana virus is the most common cause of meningitis from May to October.

160 We developed the first bacterial meningitis global database by compiling monthly incidenc

161 600-282 400) incident cases of cryptococcal meningitis globally in 2014.

162 No persons with cryptococcal meningitis had negative fingersticks.

163 ir and vancomycin during management of acute meningitis has been explored.

164 eir role in the pathogenesis of pneumococcal meningitis has not been addressed.

165 A substantial reduction in bacterial meningitis has occurred in the UK following successful i

166 roup B (MnB) is a leading cause of bacterial meningitis; however, MnB is most commonly associated wit

167 occus (GBS) is the leading cause of neonatal meningitis; however, the molecular mechanisms that regul

168 evaluated the prevalence of ventriculitis or meningitis in 13 Italian ICUs.

169 rospinal fluid samples detected lymphomatous meningitis in 2 patients.

170 composite standard, we detected tuberculous meningitis in 22 (17%) of 129 participants.

171 med to describe features of Escherichia coli meningitis in a large population of children and the mol

172 Cryptococcus is the most common cause of meningitis in adults living with HIV in sub-Saharan Afri

173 t emerged as an important cause of bacterial meningitis in adults.

174 s emerged as an important cause of bacterial meningitis in adults.

175 yptococcus is the most common cause of adult meningitis in Africa.

176 c) was developed to control epidemic group A meningitis in Africa.

177 several decades, the incidence of bacterial meningitis in children has decreased but there remains a

178 Most childhood meningitis in developed countries is now caused by virus

179 Long-term trends in paediatric viral meningitis in England have not previously been reported.

180 ological trends over time in childhood viral meningitis in England.

181 hogen that can cause life-threatening fungal meningitis in immunocompromised individuals.

182 lous meningitis (TBM) is a frequent cause of meningitis in individuals with human immunodeficiency vi

183 the treatment of HIV-associated cryptococcal meningitis in Mbarara, Uganda.

184 ) is a leading cause of bacterial sepsis and meningitis in newborns.

185 the progression and outcome of pneumococcal meningitis in Rag1(-/-) mice lacking functional B and T

186 mortality among patients with other forms of meningitis in some populations, but their use is unteste

187 acteristics of nontyphoidal Salmonella (NTS) meningitis in South Africa, where human immunodeficiency

188 accounting for 33%-63% of all cases of adult meningitis in sub-Saharan Africa and >500 000 deaths ann

189 ation strategy for long-term control of MenA meningitis in the African meningitis belt.

190 X are among the leading causes of bacterial meningitis in the African meningitis belt.

191 igns at presentation independently predicted meningitis in the derivation cohort and were tested as a

192 can describe the typical annual incidence of meningitis in the prevaccine era, with irregular epidemi

193 ngitidis has been a major cause of bacterial meningitis in the sub-Saharan region of Africa in the me

194 lt patients with HIV-associated cryptococcal meningitis in Vietnam, Thailand, Indonesia, Laos, Uganda

195 enAfriVac), in 2010, we analyzed the data on meningitis incidence and case fatality from countries re

196 nnual age-specific admission rates for viral meningitis, including specific viral aetiologies, in chi

197 Anthrax meningitis is a common manifestation of B. anthracis inf

198 Cryptococcal meningitis is a metric of HIV treatment programme failur

199 GBS meningitis is an important risk factor for moderate to s

200 of CSF BDG testing for other types of fungal meningitis is needed.

201 Although the pathogenesis of bacterial meningitis is not completely understood, knowledge of ba

202 ical features alone cannot determine whether meningitis is present and analysis of cerebrospinal flui

203 Pneumococcal meningitis is the most frequent and critical type of bac

204 Acute bacterial meningitis is widely considered to result from bacteremi

205 ensis, while a primary cause of eosinophilic meningitis, is rarely a cause of FUO.

206 sing home, recent surgery, septic shock, NF, meningitis, isolated bacteremia, pneumonia, emm type 1 o

207 nd for patients with endocarditis, bacterial meningitis, lymphoma/leukemia, HIV/AIDS, internal organ

208 Using a bacteremia-derived meningitis model and mutant mice, as well as antibodies

209 In a meningitis model, MRP14-deficient mice showed a better r

210 er as cases of encephalopathy, encephalitis, meningitis, myelitis, and seizures have also been report

211 ty presented with septicemia (n = 63 [49%]), meningitis (n = 16 [12%]) or both (n = 21 [16%]); howeve

212 e occurrence of serious infection (sepsis or meningitis), necrotizing enterocolitis, or mortality dur

213 ission had a sensitivity for finding anthrax meningitis of 89% (83%) in the adult (pediatric) validat

214 ensively assess seasonal trends in bacterial meningitis on a global scale.

215 All 18 studies followed up survivors of GBS meningitis; only 5 of these studies also followed up sur

216 Adult patients (>/=18 years) with meningitis or encephalitis by International Classificati

217 ement decisions, and outcomes of adults with meningitis or encephalitis in the United States (US) are

218 A total of 26429 patients with meningitis or encephalitis were identified.

219 ion, it may disseminate to the CNS and cause meningitis or meningoencephalitis.

220 n can mimic other conditions such as aseptic meningitis or pituitary adenomas.

221 symptoms, clinical presentation of suspected meningitis or pneumonia, and evidence of radiographic pn

222 tions did not seem to apply to meningococcal meningitis or viral meningitis.

223 pneumococcal (n = 553), or viral (n = 1,433) meningitis or with herpes simplex encephalitis (n = 115)

224 R = 8.3; CI, 4.9-13.9; P < .0001), bacterial meningitis (OR = 3.8; CI, 1.2-12.0; P = .023), fungal me

225 s (OR = 3.8; CI, 1.2-12.0; P = .023), fungal meningitis (OR = 59.1; CI, 14.1-247.8; P < .0001), inter

226 e-threatening infections, such as pneumonia, meningitis, or sepsis.

227 the Ebola outbreak response and measles and meningitis outbreaks; and strengthening the integrated d

228 py in immunocompromised patients with herpes meningitis (P < .05), but not in the 27 patient-episodes

229 With fluconazole 1200 mg/d therapy, 68% of meningitis patients (23 of 34) died within 3 months.

230 brospinal fluid (CSF) samples from suspected meningitis patients of all ages were examined by traditi

231 ity pension in former meningococcal or viral meningitis patients versus members of the comparison coh

232 al conjugate vaccine (PCV13) on pneumococcal meningitis (PM) in US children is unknown.

233 loss is an important sequela of pneumococcal meningitis (PM), occurring in up to 30% of survivors.

234 up to 30% of patients surviving pneumococcal meningitis (PM).

235 jor global public health problems, including meningitis, pneumonia and septicaemia.

236 brospinal fluid from patients with suspected meningitis, presenting to Queen Elizabeth Central Hospit

237 Most patients with HSV meningitis rapidly improve, but immunocompromised hosts

238 In 6 episodes (14.3%), patients with meningitis received no antivirals, whereas the remaining

239 ances in antimicrobial therapy, pneumococcal meningitis remains a life-threatening disease.

240 Cryptococcal meningitis remains a significant cause of death among hu

241 clear, the role of antiviral therapy in HSV meningitis remains controversial.

242 Plasma CRAG titers >1:160 predict meningitis, requiring more intensive antifungal therapy.

243 were drafted at an international tuberculous meningitis research meeting organized by the Oxford Univ

244 emia without meningitis, and septicemia with meningitis, respectively.

245 Altered mental status in cryptococcal meningitis results in poorer survival, but underlying ca

246 In this large study of 325 cases of E. coli meningitis, risk factors of severe disease or death were

247 e used in the derivation of the Malawi Adult Meningitis Score (MAMS) nomogram.

248 vity had a latitudinal trend, with bacterial meningitis seasons peaking during the winter months in c

249 acteria causes a range of diseases including meningitis, septicaemia, gonorrhoea and endocarditis, an

250 ns were classified as groups 1-3 that caused meningitis, septicemia without meningitis, and septicemi

251 erichia coli K1-mediated neonatal sepsis and meningitis, such as a strong age dependency and developm

252 compiled and analysed nationwide case-based meningitis surveillance data in Niger.

253 for the African meningitis belt, an enhanced meningitis surveillance network was established.

254 Of meningitis survivors, 32% (95% CI, 25%-38%) had NDI at 1

255 e variants in a gene region and pneumococcal meningitis susceptibility yielded one significant associ

256 enetic variants associated with pneumococcal meningitis susceptibility.

257 children admitted to hospital with bacterial meningitis symptoms but negative diagnosis.

258 Tuberculous meningitis (TBM) is a frequent cause of meningitis in in

259 Tuberculous meningitis (TBM) is a severe complication of tuberculosi

260 Drug-resistant tuberculous meningitis (TBM) is difficult to diagnose and treat.

261 Tuberculous meningitis (TBM) is the most devastating form of tubercu

262 Tuberculous meningitis (TBM) is the most severe form of tuberculous

263 Tuberculous meningitis (TBM) leads to death or disability in half th

264 Tuberculous meningitis (TBM) remains a major cause of death and disa

265 high morbidity and mortality of tuberculous meningitis (TBM), but the link between inflammation and

266 ltra detected significantly more tuberculous meningitis than did either Xpert or culture.

267 of survival among patients with tuberculous meningitis than standard treatment.

268 ains that cause urinary tract infections and meningitis, they have not been linked to translocation t

269 tractive treatment strategy for cryptococcal meningitis, though the rising price may be creating acce

270 ree were categorised as probable tuberculous meningitis, three as possible tuberculous meningitis, an

271 eported severity ranges from a self-limiting meningitis to a rapidly fatal meningoencephalitis with m

272 entified the optimal cutoff value for proven meningitis to be 66 pg/ml (sensitivity, 100%; specificit

273 ficity, 94%) and that for probable or proven meningitis to be 66 pg/ml (sensitivity, 91%; specificity

274 nce data on suspected and confirmed cases of meningitis to quantify vaccine impact.

275 BIs), defined as bacteremia and/or bacterial meningitis, using complete blood cell count parameters.

276 the progression and outcome of pneumococcal meningitis, using Kaplan-Meier survival curves, bacterio

277 , PsA-TT (MenAfriVac), developed through the Meningitis Vaccine Project and manufactured by the Serum

278 ] cohorts), while presence of 2 or more made meningitis very likely (LR+ = 26.5 [30.0]).

279 Meningitis was diagnosed in nearly half the fatal cases

280 Survival of anthrax meningitis was predicted by treatment with a bactericida

281 Globally, cryptococcal meningitis was responsible for 15% of AIDS-related death

282 Anthrax meningitis was unlikely in the absence of any of these s

283 ortant role in the pathogenesis of bacterial meningitis, we examined whether functional polymorphisms

284 psies from patients who died of pneumococcal meningitis, we observe that pneumococci colocalize with

285 atients with a first episode of cryptococcal meningitis were enrolled, and their immune responses wer

286 d, 172 HIV-infected adults with cryptococcal meningitis were enrolled.

287 Annual global deaths from cryptococcal meningitis were estimated at 181 100 (95% CI 119 400-234

288 sociated with susceptibility to pneumococcal meningitis were rs139064549 on chromosome 1 in the COL11

289 o fever onset within patients with bacterial meningitis when compared with both aseptic and nonmening

290 d treatment is underutilized in pneumococcal meningitis, where it has shown to decrease mortality.

291 Bacterial meningitis, which is caused mainly by Neisseria meningit

292 d HIV-infected individuals with cryptococcal meningitis who presented to Mulago Hospital in Kampala,

293 lts with a clinical diagnosis of tuberculous meningitis who were admitted to one of two Vietnamese ho

294 ants, 138 (93%) had evidence of cryptococcal meningitis with a positive CSF CRAG.

295 s and in 39.3% of patients with pneumococcal meningitis, with an associated decrease in mortality (6.

296 osis of these three major types of bacterial meningitis, with high sensitivity and specificity.

297 nd 11 from patients with suspected microbial meningitis without fungal diagnosis, for (1,3)-beta-gluc

298 e smoke increased the risk of bacteremia and meningitis without prior lung infection.

299 tidis causes 500 000 cases of septicemia and meningitis worldwide annually, with approximately 200 ca

300 throat, scarlet fever, pneumonia, bacterial meningitis, yeast infections, urinary tract infections,